Acorda Therapeutics Looks at Major Expansion on Everett Avenue

Riding on the heels of what is expected to be the approval of a new Parkinson’s disease treatment drug, Acorda Therapeutics of 190 Everett Ave. has announced a proposal to significantly expand its existing operations.

The company has been located at its facility for some time, and operates under a lease from a New York company that is very active in Greater Boston. Now, however, they received good news from the Food and Drug Administration (FDA) about the likely approval of its new drug INBRIJA, a drug that delivers relief to Parkinson’s patients through an inhaler rather than a pill. It is expected it could be approved in October, leading to the need to ramp up manufacturing of it by 2019.

“Acorda Therapeutics seeks to expand operations at its manufacturing site at 190 Everett Avenue where it will support the global market for the Parkinson’s disease treatment INBRIJA and will ultimately provide the capability to support simultaneous manufacture of multiple products…The proposed project is an immediate expansion and upgrade of manufacturing and warehouse space. Acorda anticipates that the project will create 20 to 25 full-time, well-paying new jobs with targeted construction completion by Quarter 3 2019. This is a first step toward a long-term master plan vision that could ultimately create 100 new jobs and include a substantial capital investment.”

A spokesman for the company declined to comment now as it was too early in the process.

City Manager Tom Ambrosino said he is 100 percent in favor of the proposal and will speak in favor.

“I am hoping that it will be nothing for smooth sailing for them,” he said. “This is a very exciting proposal and I am 100 percent in favor. It has a lot of potential for Chelsea.”

The project includes a new manufacturing fit out of existing space in one of the buildings to house specialized equipment. It will also include the demolition of the 115-foot smoke stack and a demolition and reconstruction of another existing building on the site.

The manufacturing building will be unchanged in its footprint, though more than 2,000 sq. ft. of space will be added to the top floor for manufacturing.

The reconstruction of the demolished building will add nearly 4,000 sq. ft. of new floor area for manufacturing, shipping and warehouse space.

The identify that the new configuration will have at least 121 parking spaces, and they will require a zoning variance for the building height of the warehouse – where the requirements are no higher than 25 feet and the new building would be 66 feet. The existing building is now at 44 feet tall.

" Seth Daniel : ."